Pharmacological Therapy of Benign Prostate Syndrome

The document discussed various aspects of the pharmacological treatment of benign prostatic syndrome (BPS). It highlighted that disease progression was evident in over 80% of patients within 3 to 5 years, particularly in those with a prostate volume greater than 40 ml. Tadalafil was noted to reduce acute urinary retention over the long term, while α-blockers like Tamsulosin and Alfuzosin were equally effective for men with lower urinary tract symptoms (LUTS). The combination of Finasterid and Doxazosin significantly reduced the risk of urinary retention more than individual treatments. Additionally, the combination of Solifenacin and Tamsulosin was more effective in reducing bladder storage symptoms than Tamsulosin alone. The document also mentioned that Finasterid therapy required PSA value adjustments for prostate cancer detection, and that orthostatic hypotension was a typical side effect of Tadalafil.